Related Experiment Video
Updated: Jun 11, 2026
13:47
Efficient Recombinant Parvovirus Production with the Help of Adenovirus-derived Systems
Published on: April 23, 2012
First 20 years with recombinant FVIIa (NovoSeven)
Summary
Recombinant activated factor VIIa (rFVIIa) effectively treats bleeding in hemophilic patients with inhibitors, demonstrating high efficacy in surgery and home treatment. Its mechanism involves enhancing thrombin generation on activated platelets, offering potential beyond hemophilia treatment.
Area of Science:
- Hematology and Thrombosis
- Pharmacology and Drug Development
- Biotechnology and Recombinant Protein Therapeutics
Background:
- Development of recombinant activated factor VIIa (rFVIIa) addresses the need for effective hemostatic agents in hemophilic patients with inhibitors.
- Early studies with plasma-derived FVIIa showed promise, leading to the production of rFVIIa for broader clinical application.
- rFVIIa received regulatory approval in the EU, USA, and Japan for treating factor inhibitors in hemophilia.
Purpose of the Study:
- To review the development, efficacy, and safety of recombinant activated factor VIIa (rFVIIa) in managing bleeding disorders.
- To explore the mechanism of action of rFVIIa in promoting hemostasis, particularly in the absence of cofactors.
- To discuss the evolving applications of rFVIIa, including home treatment, prophylaxis, and potential uses beyond hemophilia.
Main Methods:
- Review of clinical studies and regulatory approvals for rFVIIa (NovoSeven).
- Analysis of efficacy rates in severe bleeding and major surgeries.
- In vitro studies using a cell-based model to elucidate the mechanism of action of rFVIIa on platelet activation and thrombin generation.
Main Results:
- rFVIIa demonstrated an efficacy rate of approximately 90% in controlled studies for severe bleeding and major surgeries, with no significant safety concerns.
- The drug has enabled elective major surgery in hemophilia patients with inhibitors and shown promise in home treatment and prophylaxis.
- In vitro studies confirmed that rFVIIa enhances thrombin generation on activated platelets, independent of FVIII/FIX, forming a stable fibrin clot.
Conclusions:
- rFVIIa is a well-established and effective treatment for hemophilic patients with inhibitors, facilitating surgical procedures and improving patient management.
- The mechanism of action, involving enhanced thrombin generation, suggests potential therapeutic applications in other conditions with impaired hemostasis.
- Ongoing research and clinical experience continue to refine dosing strategies and expand the understanding of rFVIIa's role in coagulation.
Related Concept Videos
01:09Recombinant DNA
Overview
01:09Recombinant DNA
Overview
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...